A top broker for CBRE is moving over to the development side as president of Beacon Capital Partners’ life science platform.

Steve Purpura will lead the Boston developer’s lab space expansion in markets including Boston, Philadelphia, San Francisco and Seattle, Beacon Capital announced today. Beacon manages a 2.6-million-square-foot portfolio of life science properties and has another 3 million square feet in development.

Purpura previously headed CBRE’s Boston Consulting practice and was lead life science broker for its Northeast region. He joined CBRE in 2018 as the brokerage hired 48 brokers and staff who previously worked at Transwestern’s Boston offices, where Purpura was the Northeast market lead.

Purpura represented Boston Landing owners NB Development in their negotiations with Proteostasis Therapeutics, one of the first life science companies to expand into the Brighton neighborhood, and represented Collegium Pharmaceuticals in its move to 100 Technology Center Drive in Stoughton. On the investment sales side, Purpura brokered the acquisition of two Sanofi Genzyme properties in Framingham to King Street Properties.

“Beacon is incredibly well positioned to capture the immense market opportunity in the development of specialty-built life science real estate and I look forward to working with the team to add to the firm’s storied legacy of investing in iconic real estate,” Purpura said in a statement.